バイオメディカルにおける人工知能市場：コンポーネント、テクノロジー、アプリケーション、エンドユーザー別-2025-2030年の世界予測

バイオメディカルにおける人工知能市場の2023年の市場規模は47億米ドルで、2024年には57億8,000万米ドルに達すると予測され、CAGR 24.18％で成長し、2030年には214億米ドルに達すると予測されています。

バイオメディカル分野における人工知能（AI）の応用範囲は、創薬、ゲノム、医療用画像処理から患者モニタリング、個別化医療まで多岐にわたる。AIは、大規模なデータセットを迅速に分析し、複雑なパターンを特定し、結果を予測する能力により、意思決定プロセスや業務効率を高めるために不可欠です。その応用として、機械学習、自然言語処理、ロボットによるプロセス自動化などのAI技術は、臨床試験の最適化、診断精度の向上、医薬品開発プロセスの迅速化に採用されています。最終用途分野には、ヘルスケアプロバイダー、製薬会社、研究機関などが含まれます。市場成長の主な原動力は、精密医療に対する需要の高まり、AIの技術的進歩、ヘルスケアデータの増大です。さらに、AIとモノのインターネット（IoT）の統合を支援する政府のイニシアチブは、生物医学アプリケーションにおけるAIの取り込みを強化しています。

成長に影響を与える主な要因としては、ヘルスケア支出の増加、良好な規制環境、テック企業とヘルスケアプロバイダーとの協業などが挙げられます。しかし、市場の拡大には、データプライバシーに対する懸念、高い導入コスト、AIと生物医学の熟練専門家の不足が課題となっています。こうしたハードルにもかかわらず、疾病の早期発見とモニタリングのためのAI搭載ツールの開発には機会があふれており、革新的なアプローチと学際的なコラボレーションが求められています。こうした機会を活用しようとする企業にとって、満たされていない臨床ニーズに対応するAIソリューションをターゲットとし、学術・研究機関と協力することが有益となる可能性があります。

イノベーションは、AIとウェアラブル技術の統合、患者に特化した予測のための包括的なAIモデルの開発、非構造化データを効果的に扱うための教師なし学習手法の探求に焦点を当てるべきです。市場の競争は激しく、急速に進化しており、既存のヘルスケア事業体とハイテク新興企業の両方から多額の投資が行われています。企業は、このダイナミックな環境で優位に立つために、規制の変化や技術の進歩を継続的に監視する必要があります。イノベーションと戦略的コラボレーションを促進することで、企業は現在の制約を克服できるだけでなく、新たな成長機会を獲得することもできます。

市場力学：急速に進化するバイオメディカルにおける人工知能市場の主要市場インサイトを公開

バイオメディカルにおける人工知能市場は、需要と供給のダイナミックな相互作用によって変貌を遂げています。このような市場力学の進化を理解することで、企業は十分な情報に基づいた投資決定、戦略的決定の精緻化、そして新たなビジネスチャンスの獲得に備えることができます。こうした動向を包括的に把握することで、企業は政治的、地理的、技術的、社会的、経済的な領域にわたる様々なリスクを軽減することができるとともに、消費者行動とそれが製造コストや購買動向に与える影響をより明確に理解することができます。

• 市場促進要因
  • 世界のバイオメディカル分野のデジタル化と研究の増加
  • 創薬・開発活動の急増
  • 個別化医療とカスタマイズ医療に対する需要の高まり
• 市場抑制要因
  • 生物医学におけるAIに関連する高コスト
• 市場機会
  • 生物医学ソリューションにおけるAIの技術的進歩
  • 生物医学ソリューションにおけるAI開発のための有利な投資環境
• 市場の課題
  • データプライバシーとセキュリティに関する懸念

ポーターのファイブフォース：バイオメディカルにおける人工知能市場をナビゲートする戦略ツール

ポーターのファイブフォースフレームワークは、市場情勢の競合情勢を理解するための重要なツールです。ポーターのファイブフォース・フレームワークは、企業の競争力を評価し、戦略的機会を探るための明確な手法を提供します。このフレームワークは、企業が市場内の勢力図を評価し、新規事業の収益性を判断するのに役立ちます。これらの洞察により、企業は自社の強みを活かし、弱みに対処し、潜在的な課題を回避することで、より強靭な市場でのポジショニングを確保することができます。

PESTLE分析：バイオメディカルにおける人工知能市場における外部からの影響の把握

外部マクロ環境要因は、バイオメディカルにおける人工知能市場の業績ダイナミクスを形成する上で極めて重要な役割を果たします。政治的、経済的、社会的、技術的、法的、環境的要因の分析は、これらの影響をナビゲートするために必要な情報を提供します。PESTLE要因を調査することで、企業は潜在的なリスクと機会をよりよく理解することができます。この分析により、企業は規制、消費者の嗜好、経済動向の変化を予測し、先を見越した積極的な意思決定を行う準備ができます。

市場シェア分析バイオメディカルにおける人工知能市場における競合情勢の把握

バイオメディカルにおける人工知能市場の詳細な市場シェア分析により、ベンダーの業績を包括的に評価することができます。企業は、収益、顧客ベース、成長率などの主要指標を比較することで、競争上のポジショニングを明らかにすることができます。この分析により、市場の集中、断片化、統合の動向が明らかになり、ベンダーは競争が激化する中で自社の地位を高める戦略的意思決定を行うために必要な知見を得ることができます。

FPNVポジショニング・マトリックスバイオメディカルにおける人工知能市場におけるベンダーのパフォーマンス評価

FPNVポジショニングマトリックスは、バイオメディカルにおける人工知能市場においてベンダーを評価するための重要なツールです。このマトリックスにより、ビジネス組織はベンダーのビジネス戦略と製品満足度に基づき評価することで、目標に沿った十分な情報に基づいた意思決定を行うことができます。4つの象限によってベンダーを明確かつ正確にセグメント化し、戦略目標に最適なパートナーやソリューションを特定することができます。

戦略分析と推奨バイオメディカルにおける人工知能市場における成功への道筋を描く

バイオメディカルにおける人工知能市場の戦略分析は、世界市場でのプレゼンス強化を目指す企業にとって不可欠です。主要なリソース、能力、業績指標を見直すことで、企業は成長機会を特定し、改善に取り組むことができます。このアプローチにより、競合情勢における課題を克服し、新たなビジネスチャンスを活かして長期的な成功を収めるための体制を整えることができます。

本レポートでは、主要な注目分野を網羅した市場の包括的な分析を提供しています：

1.市場の浸透度：現在の市場環境の詳細なレビュー、主要企業による広範なデータ、市場でのリーチと全体的な影響力の評価。

2.市場の開拓度：新興市場における成長機会を特定し、既存分野における拡大可能性を評価し、将来の成長に向けた戦略的ロードマップを提供します。

3.市場の多様化：最近の製品発売、未開拓の地域、業界の主要な進歩、市場を形成する戦略的投資を分析します。

4.競合の評価と情報：競合情勢を徹底的に分析し、市場シェア、事業戦略、製品ポートフォリオ、認証、規制当局の承認、特許動向、主要企業の技術進歩などを検証します。

5.製品開発およびイノベーション：将来の市場成長を促進すると期待される最先端技術、研究開発活動、製品イノベーションをハイライトしています。

また、利害関係者が十分な情報を得た上で意思決定できるよう、重要な質問にも答えています：

1.現在の市場規模と今後の成長予測は？

2.最高の投資機会を提供する製品、セグメント、地域はどこか？

3.市場を形成する主な技術動向と規制の影響とは？

4.主要ベンダーの市場シェアと競合ポジションは？

5.ベンダーの市場参入・撤退戦略の原動力となる収益源と戦略的機会は何か？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • 世界中でバイオメディカル分野におけるデジタル化と調査が増加
    • 医薬品の発見と開発活動の急増
    • パーソナライズされたカスタマイズされた医療の需要の高まり
  • 抑制要因
    • バイオメディカルにおけるAIの高コスト
  • 機会
    • バイオメディカルソリューションにおけるAIの技術的進歩
    • バイオメディカルソリューションにおけるAI開発のための好ましい投資情勢
  • 課題
    • データのプライバシーとセキュリティに関する懸念
• 市場セグメンテーション分析
  • タイプ：AIベースのバイオメディカルソフトウェアの大幅な普及
  • 用途：医薬品の発見と開発における広範な使用
  • エンドユーザー：製薬会社におけるAIベースのバイオメディカルソリューションの応用拡大
• ポーターのファイブフォース分析
• PESTEL分析
  • 政治的
  • 経済
  • 社交
  • 技術的
  • 法律上
  • 環境

第6章 バイオメディカルにおける人工知能市場：コンポーネント別

• ハードウェア
• サービス
• ソフトウェア

第7章 バイオメディカルにおける人工知能市場：技術別

• コンピュータビジョン
• コンテキスト認識コンピューティング
• 機械学習
• 自然言語処理
• クエリ方法

第8章 バイオメディカルにおける人工知能市場：用途別

• 臨床意思決定支援
• 臨床試験コーディネーターおよび治験責任医師
• 医薬品の発見と開発
• ゲノミクスと個別化医療
• 医療画像診断と放射線診断

第9章 バイオメディカルにおける人工知能市場：エンドユーザー別

• バイオテクノロジー企業
• 病院と診断センター
• 製薬会社
• 調査機関

第10章 南北アメリカのバイオメディカルにおける人工知能市場

• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第11章 アジア太平洋地域のバイオメディカルにおける人工知能市場

• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第12章 欧州・中東・アフリカのバイオメディカルにおける人工知能市場

• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第13章 競合情勢

• 市場シェア分析2023
• FPNVポジショニングマトリックス, 2023
• 競合シナリオ分析
  • Bionl.AI、ノーコードバイオメディカル調査のための革新的なプラットフォームを発表
  • Epistemic AIがBIOでバイオメディカルGPTを発表
  • NIH、バイオメディカルにおける人工知能と行動調査の利用を拡大するBridge2AIプログラムを開始
• 戦略分析と提言

企業一覧

• AiCure, LLC
• Arterys Inc.
• Aspen Technology Inc
• Atomwise Inc
• Augmedix, Inc.
• Behold.ai Technologies Limited
• BenevolentAI SA
• BioSymetrics Inc.
• BPGbio Inc.
• Butterfly Network, Inc.
• Caption Health, Inc. by GE Healthcare
• Cloud Pharmaceuticals, Inc.
• CloudMedX Inc.
• Corti ApS
• Cyclica Inc
• Deargen Inc
• Deep Genomics Incorporated
• Euretos Services BV
• Exscientia plc
• Google, LLC by Alphabet, Inc.
• Insilico Medicine
• Intel Corporation
• International Business Machines Corporation
• InveniAI LLC
• Isomorphic Labs
• Novo Nordisk A/S
• Sanofi SA
• Turbine Ltd.
• Viseven Europe OU
• XtalPi Inc.

LIST OF FIGURES

• FIGURE 1. ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET RESEARCH PROCESS
• FIGURE 2. ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, 2023 VS 2030
• FIGURE 3. GLOBAL ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. GLOBAL ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 5. GLOBAL ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 6. GLOBAL ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY COMPONENTS, 2023 VS 2030 (%)
• FIGURE 7. GLOBAL ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY COMPONENTS, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 8. GLOBAL ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY TECHNOLOGY, 2023 VS 2030 (%)
• FIGURE 9. GLOBAL ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY TECHNOLOGY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 10. GLOBAL ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
• FIGURE 11. GLOBAL ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 12. GLOBAL ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY END-USERS, 2023 VS 2030 (%)
• FIGURE 13. GLOBAL ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY END-USERS, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 14. AMERICAS ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 15. AMERICAS ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 16. UNITED STATES ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY STATE, 2023 VS 2030 (%)
• FIGURE 17. UNITED STATES ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 18. ASIA-PACIFIC ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 19. ASIA-PACIFIC ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 20. EUROPE, MIDDLE EAST & AFRICA ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 21. EUROPE, MIDDLE EAST & AFRICA ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 22. ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SHARE, BY KEY PLAYER, 2023
• FIGURE 23. ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

• TABLE 1. ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
• TABLE 3. GLOBAL ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. GLOBAL ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 5. GLOBAL ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 6. ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET DYNAMICS
• TABLE 7. GLOBAL ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY COMPONENTS, 2018-2030 (USD MILLION)
• TABLE 8. GLOBAL ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY HARDWARE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. GLOBAL ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY SERVICES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. GLOBAL ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY SOFTWARE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 11. GLOBAL ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 12. GLOBAL ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY COMPUTER VISION, BY REGION, 2018-2030 (USD MILLION)
• TABLE 13. GLOBAL ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY CONTEXT-AWARE COMPUTING, BY REGION, 2018-2030 (USD MILLION)
• TABLE 14. GLOBAL ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY MACHINE LEARNING, BY REGION, 2018-2030 (USD MILLION)
• TABLE 15. GLOBAL ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY NATURAL LANGUAGE PROCESSING, BY REGION, 2018-2030 (USD MILLION)
• TABLE 16. GLOBAL ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY QUERYING METHOD, BY REGION, 2018-2030 (USD MILLION)
• TABLE 17. GLOBAL ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 18. GLOBAL ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY CLINICAL DECISION SUPPORT, BY REGION, 2018-2030 (USD MILLION)
• TABLE 19. GLOBAL ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY CLINICAL TRIAL COORDINATORS & INVESTIGATORS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 20. GLOBAL ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, BY REGION, 2018-2030 (USD MILLION)
• TABLE 21. GLOBAL ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY GENOMICS & PERSONALIZED MEDICINE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 22. GLOBAL ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY MEDICAL IMAGING & RADIOLOGY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 23. GLOBAL ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 24. GLOBAL ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY BIOTECHNOLOGY FIRMS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 25. GLOBAL ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY HOSPITALS & DIAGNOSTIC CENTERS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 26. GLOBAL ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 27. GLOBAL ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY RESEARCH INSTITUTIONS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 28. AMERICAS ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY COMPONENTS, 2018-2030 (USD MILLION)
• TABLE 29. AMERICAS ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 30. AMERICAS ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 31. AMERICAS ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 32. AMERICAS ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 33. ARGENTINA ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY COMPONENTS, 2018-2030 (USD MILLION)
• TABLE 34. ARGENTINA ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 35. ARGENTINA ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 36. ARGENTINA ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 37. BRAZIL ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY COMPONENTS, 2018-2030 (USD MILLION)
• TABLE 38. BRAZIL ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 39. BRAZIL ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 40. BRAZIL ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 41. CANADA ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY COMPONENTS, 2018-2030 (USD MILLION)
• TABLE 42. CANADA ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 43. CANADA ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 44. CANADA ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 45. MEXICO ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY COMPONENTS, 2018-2030 (USD MILLION)
• TABLE 46. MEXICO ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 47. MEXICO ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 48. MEXICO ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 49. UNITED STATES ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY COMPONENTS, 2018-2030 (USD MILLION)
• TABLE 50. UNITED STATES ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 51. UNITED STATES ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 52. UNITED STATES ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 53. UNITED STATES ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 54. ASIA-PACIFIC ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY COMPONENTS, 2018-2030 (USD MILLION)
• TABLE 55. ASIA-PACIFIC ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 56. ASIA-PACIFIC ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 57. ASIA-PACIFIC ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 58. ASIA-PACIFIC ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 59. AUSTRALIA ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY COMPONENTS, 2018-2030 (USD MILLION)
• TABLE 60. AUSTRALIA ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 61. AUSTRALIA ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 62. AUSTRALIA ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 63. CHINA ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY COMPONENTS, 2018-2030 (USD MILLION)
• TABLE 64. CHINA ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 65. CHINA ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 66. CHINA ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 67. INDIA ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY COMPONENTS, 2018-2030 (USD MILLION)
• TABLE 68. INDIA ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 69. INDIA ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 70. INDIA ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 71. INDONESIA ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY COMPONENTS, 2018-2030 (USD MILLION)
• TABLE 72. INDONESIA ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 73. INDONESIA ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 74. INDONESIA ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 75. JAPAN ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY COMPONENTS, 2018-2030 (USD MILLION)
• TABLE 76. JAPAN ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 77. JAPAN ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 78. JAPAN ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 79. MALAYSIA ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY COMPONENTS, 2018-2030 (USD MILLION)
• TABLE 80. MALAYSIA ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 81. MALAYSIA ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 82. MALAYSIA ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 83. PHILIPPINES ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY COMPONENTS, 2018-2030 (USD MILLION)
• TABLE 84. PHILIPPINES ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 85. PHILIPPINES ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 86. PHILIPPINES ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 87. SINGAPORE ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY COMPONENTS, 2018-2030 (USD MILLION)
• TABLE 88. SINGAPORE ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 89. SINGAPORE ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 90. SINGAPORE ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 91. SOUTH KOREA ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY COMPONENTS, 2018-2030 (USD MILLION)
• TABLE 92. SOUTH KOREA ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 93. SOUTH KOREA ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 94. SOUTH KOREA ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 95. TAIWAN ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY COMPONENTS, 2018-2030 (USD MILLION)
• TABLE 96. TAIWAN ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 97. TAIWAN ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 98. TAIWAN ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 99. THAILAND ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY COMPONENTS, 2018-2030 (USD MILLION)
• TABLE 100. THAILAND ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 101. THAILAND ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 102. THAILAND ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 103. VIETNAM ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY COMPONENTS, 2018-2030 (USD MILLION)
• TABLE 104. VIETNAM ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 105. VIETNAM ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 106. VIETNAM ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 107. EUROPE, MIDDLE EAST & AFRICA ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY COMPONENTS, 2018-2030 (USD MILLION)
• TABLE 108. EUROPE, MIDDLE EAST & AFRICA ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 109. EUROPE, MIDDLE EAST & AFRICA ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 110. EUROPE, MIDDLE EAST & AFRICA ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 111. EUROPE, MIDDLE EAST & AFRICA ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 112. DENMARK ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY COMPONENTS, 2018-2030 (USD MILLION)
• TABLE 113. DENMARK ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 114. DENMARK ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 115. DENMARK ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 116. EGYPT ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY COMPONENTS, 2018-2030 (USD MILLION)
• TABLE 117. EGYPT ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 118. EGYPT ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 119. EGYPT ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 120. FINLAND ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY COMPONENTS, 2018-2030 (USD MILLION)
• TABLE 121. FINLAND ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 122. FINLAND ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 123. FINLAND ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 124. FRANCE ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY COMPONENTS, 2018-2030 (USD MILLION)
• TABLE 125. FRANCE ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 126. FRANCE ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 127. FRANCE ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 128. GERMANY ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY COMPONENTS, 2018-2030 (USD MILLION)
• TABLE 129. GERMANY ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 130. GERMANY ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 131. GERMANY ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 132. ISRAEL ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY COMPONENTS, 2018-2030 (USD MILLION)
• TABLE 133. ISRAEL ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 134. ISRAEL ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 135. ISRAEL ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 136. ITALY ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY COMPONENTS, 2018-2030 (USD MILLION)
• TABLE 137. ITALY ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 138. ITALY ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 139. ITALY ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 140. NETHERLANDS ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY COMPONENTS, 2018-2030 (USD MILLION)
• TABLE 141. NETHERLANDS ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 142. NETHERLANDS ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 143. NETHERLANDS ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 144. NIGERIA ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY COMPONENTS, 2018-2030 (USD MILLION)
• TABLE 145. NIGERIA ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 146. NIGERIA ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 147. NIGERIA ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 148. NORWAY ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY COMPONENTS, 2018-2030 (USD MILLION)
• TABLE 149. NORWAY ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 150. NORWAY ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 151. NORWAY ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 152. POLAND ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY COMPONENTS, 2018-2030 (USD MILLION)
• TABLE 153. POLAND ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 154. POLAND ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 155. POLAND ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 156. QATAR ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY COMPONENTS, 2018-2030 (USD MILLION)
• TABLE 157. QATAR ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 158. QATAR ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 159. QATAR ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 160. RUSSIA ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY COMPONENTS, 2018-2030 (USD MILLION)
• TABLE 161. RUSSIA ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 162. RUSSIA ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 163. RUSSIA ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 164. SAUDI ARABIA ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY COMPONENTS, 2018-2030 (USD MILLION)
• TABLE 165. SAUDI ARABIA ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 166. SAUDI ARABIA ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 167. SAUDI ARABIA ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 168. SOUTH AFRICA ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY COMPONENTS, 2018-2030 (USD MILLION)
• TABLE 169. SOUTH AFRICA ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 170. SOUTH AFRICA ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 171. SOUTH AFRICA ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 172. SPAIN ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY COMPONENTS, 2018-2030 (USD MILLION)
• TABLE 173. SPAIN ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 174. SPAIN ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 175. SPAIN ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 176. SWEDEN ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY COMPONENTS, 2018-2030 (USD MILLION)
• TABLE 177. SWEDEN ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 178. SWEDEN ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 179. SWEDEN ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 180. SWITZERLAND ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY COMPONENTS, 2018-2030 (USD MILLION)
• TABLE 181. SWITZERLAND ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 182. SWITZERLAND ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 183. SWITZERLAND ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 184. TURKEY ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY COMPONENTS, 2018-2030 (USD MILLION)
• TABLE 185. TURKEY ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 186. TURKEY ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 187. TURKEY ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 188. UNITED ARAB EMIRATES ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY COMPONENTS, 2018-2030 (USD MILLION)
• TABLE 189. UNITED ARAB EMIRATES ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 190. UNITED ARAB EMIRATES ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 191. UNITED ARAB EMIRATES ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 192. UNITED KINGDOM ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY COMPONENTS, 2018-2030 (USD MILLION)
• TABLE 193. UNITED KINGDOM ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 194. UNITED KINGDOM ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 195. UNITED KINGDOM ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 196. ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SHARE, BY KEY PLAYER, 2023
• TABLE 197. ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET, FPNV POSITIONING MATRIX, 2023

The Artificial Intelligence in Biomedical Market was valued at USD 4.70 billion in 2023, expected to reach USD 5.78 billion in 2024, and is projected to grow at a CAGR of 24.18%, to USD 21.40 billion by 2030.

The scope of artificial intelligence (AI) in the biomedical sector encompasses a wide range of applications from drug discovery, genomics, and medical imaging to patient monitoring and personalized medicine. AI is integral due to its ability to analyze large datasets rapidly, identify complex patterns, and predict outcomes, thereby enhancing decision-making processes and operational efficiencies. In application, AI technologies like machine learning, natural language processing, and robotic process automation are being employed to optimize clinical trials, improve diagnostic accuracy, and accelerate the drug development process. End-use sectors include healthcare providers, pharmaceutical companies, and research institutions. Market growth is chiefly driven by the increasing demand for precision medicine, technological advancements in AI, and a growing volume of healthcare data. Further, government initiatives supporting AI and the Internet of Things (IoT) integration bolster the uptake of AI in biomedical applications.

Key influencing growth factors include increasing healthcare expenditure, favorable regulatory environments, and collaborations between tech companies and healthcare providers. However, market expansion is challenged by concerns over data privacy, high implementation costs, and a shortage of skilled professionals in AI and biomedicine. Despite these hurdles, opportunities abound in the development of AI-powered tools for early disease detection and monitoring, which demand innovative approaches and interdisciplinary collaboration. For businesses aiming to capitalize on these opportunities, targeting AI solutions that address unmet clinical needs and collaborating with academic and research institutions may prove beneficial.

Innovation should focus on integrating AI with wearable technologies, developing comprehensive AI models for patient-specific predictions, and exploring unsupervised learning methods to handle unstructured data effectively. The nature of the market is competitive and rapidly evolving, with significant investment from both established healthcare entities and tech startups. Companies should continuously monitor regulatory changes and technological advancements to stay ahead in this dynamic environment. By fostering innovation and strategic collaboration, businesses can not only overcome present limitations but also tap into emerging opportunities for robust growth.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Artificial Intelligence in Biomedical Market

The Artificial Intelligence in Biomedical Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Increasing digitalization and research in the biomedical sector worldwide
  • Surge in drug discovery & development activities
  • Rising demand for personalized and customized medicine
• Market Restraints
  • High cost associated with AI in biomedical
• Market Opportunities
  • Technological advancements in AI in biomedical solutions
  • Favorable investment landscape for the development of AI in biomedical solutions
• Market Challenges
  • Concerns associated with data privacy and security

Porter's Five Forces: A Strategic Tool for Navigating the Artificial Intelligence in Biomedical Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Artificial Intelligence in Biomedical Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Artificial Intelligence in Biomedical Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Artificial Intelligence in Biomedical Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Artificial Intelligence in Biomedical Market

A detailed market share analysis in the Artificial Intelligence in Biomedical Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Artificial Intelligence in Biomedical Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Artificial Intelligence in Biomedical Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Artificial Intelligence in Biomedical Market

A strategic analysis of the Artificial Intelligence in Biomedical Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Artificial Intelligence in Biomedical Market, highlighting leading vendors and their innovative profiles. These include AiCure, LLC, Arterys Inc., Aspen Technology Inc, Atomwise Inc, Augmedix, Inc., Behold.ai Technologies Limited, BenevolentAI SA, BioSymetrics Inc., BPGbio Inc., Butterfly Network, Inc., Caption Health, Inc. by GE Healthcare, Cloud Pharmaceuticals, Inc., CloudMedX Inc., Corti ApS, Cyclica Inc, Deargen Inc, Deep Genomics Incorporated, Euretos Services BV, Exscientia plc, Google, LLC by Alphabet, Inc., Insilico Medicine, Intel Corporation, International Business Machines Corporation, InveniAI LLC, Isomorphic Labs, Novo Nordisk A/S, Sanofi SA, Turbine Ltd., Viseven Europe OU, and XtalPi Inc..

Market Segmentation & Coverage

This research report categorizes the Artificial Intelligence in Biomedical Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Components, market is studied across Hardware, Services, and Software.
• Based on Technology, market is studied across Computer Vision, Context-Aware Computing, Machine Learning, Natural Language Processing, and Querying Method.
• Based on Application, market is studied across Clinical Decision Support, Clinical Trial Coordinators & Investigators, Drug Discovery & Development, Genomics & Personalized Medicine, and Medical Imaging & Radiology.
• Based on End-Users, market is studied across Biotechnology Firms, Hospitals & Diagnostic Centers, Pharmaceutical Companies, and Research Institutions.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Increasing digitalization and research in the biomedical sector worldwide
    • 5.1.1.2. Surge in drug discovery & development activities
    • 5.1.1.3. Rising demand for personalized and customized medicine
  • 5.1.2. Restraints
    • 5.1.2.1. High cost associated with AI in biomedical
  • 5.1.3. Opportunities
    • 5.1.3.1. Technological advancements in AI in biomedical solutions
    • 5.1.3.2. Favorable investment landscape for the development of AI in biomedical solutions
  • 5.1.4. Challenges
    • 5.1.4.1. Concerns associated with data privacy and security
• 5.2. Market Segmentation Analysis
  • 5.2.1. Type: Significant penetration of AI-based biomedical software
  • 5.2.2. Application: Extensive use in drug discovery & development
  • 5.2.3. End-Users: Expanding applications of AI-based biomedical solutions in pharmaceutical companies
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Artificial Intelligence in Biomedical Market, by Components

• 6.1. Introduction
• 6.2. Hardware
• 6.3. Services
• 6.4. Software

7. Artificial Intelligence in Biomedical Market, by Technology

• 7.1. Introduction
• 7.2. Computer Vision
• 7.3. Context-Aware Computing
• 7.4. Machine Learning
• 7.5. Natural Language Processing
• 7.6. Querying Method

8. Artificial Intelligence in Biomedical Market, by Application

• 8.1. Introduction
• 8.2. Clinical Decision Support
• 8.3. Clinical Trial Coordinators & Investigators
• 8.4. Drug Discovery & Development
• 8.5. Genomics & Personalized Medicine
• 8.6. Medical Imaging & Radiology

9. Artificial Intelligence in Biomedical Market, by End-Users

• 9.1. Introduction
• 9.2. Biotechnology Firms
• 9.3. Hospitals & Diagnostic Centers
• 9.4. Pharmaceutical Companies
• 9.5. Research Institutions

10. Americas Artificial Intelligence in Biomedical Market

• 10.1. Introduction
• 10.2. Argentina
• 10.3. Brazil
• 10.4. Canada
• 10.5. Mexico
• 10.6. United States

11. Asia-Pacific Artificial Intelligence in Biomedical Market

• 11.1. Introduction
• 11.2. Australia
• 11.3. China
• 11.4. India
• 11.5. Indonesia
• 11.6. Japan
• 11.7. Malaysia
• 11.8. Philippines
• 11.9. Singapore
• 11.10. South Korea
• 11.11. Taiwan
• 11.12. Thailand
• 11.13. Vietnam

12. Europe, Middle East & Africa Artificial Intelligence in Biomedical Market

• 12.1. Introduction
• 12.2. Denmark
• 12.3. Egypt
• 12.4. Finland
• 12.5. France
• 12.6. Germany
• 12.7. Israel
• 12.8. Italy
• 12.9. Netherlands
• 12.10. Nigeria
• 12.11. Norway
• 12.12. Poland
• 12.13. Qatar
• 12.14. Russia
• 12.15. Saudi Arabia
• 12.16. South Africa
• 12.17. Spain
• 12.18. Sweden
• 12.19. Switzerland
• 12.20. Turkey
• 12.21. United Arab Emirates
• 12.22. United Kingdom

13. Competitive Landscape

• 13.1. Market Share Analysis, 2023
• 13.2. FPNV Positioning Matrix, 2023
• 13.3. Competitive Scenario Analysis
  • 13.3.1. Bionl.AI Launches Innovative Platform for No-Code Biomedical Research
  • 13.3.2. Epistemic AI launches biomedical GPT at BIO
  • 13.3.3. NIH launches Bridge2AI program to expand the use of artificial intelligence in biomedical and behavioral research
• 13.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. AiCure, LLC
• 2. Arterys Inc.
• 3. Aspen Technology Inc
• 4. Atomwise Inc
• 5. Augmedix, Inc.
• 6. Behold.ai Technologies Limited
• 7. BenevolentAI SA
• 8. BioSymetrics Inc.
• 9. BPGbio Inc.
• 10. Butterfly Network, Inc.
• 11. Caption Health, Inc. by GE Healthcare
• 12. Cloud Pharmaceuticals, Inc.
• 13. CloudMedX Inc.
• 14. Corti ApS
• 15. Cyclica Inc
• 16. Deargen Inc
• 17. Deep Genomics Incorporated
• 18. Euretos Services BV
• 19. Exscientia plc
• 20. Google, LLC by Alphabet, Inc.
• 21. Insilico Medicine
• 22. Intel Corporation
• 23. International Business Machines Corporation
• 24. InveniAI LLC
• 25. Isomorphic Labs
• 26. Novo Nordisk A/S
• 27. Sanofi SA
• 28. Turbine Ltd.
• 29. Viseven Europe OU
• 30. XtalPi Inc.